Luke Evnin is managing director of MPM Capital, a venture firm dedicated to life sciences investing. Dr. Evnin co-founded MPM's asset management business in 1997 to launch MPM's first venture fund and established the San Francisco office for the firm in 1999. Previously, Dr. Evnin was at Accel Partners for over seven years including four as a General Partner. At Accel Partners, he was involved in biopharmaceutical, medical device and healthcare service companies for Accel's funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University. He serves on the External Advisory Board for QB3, the Advisory Board for Mission Bay Capital (the internal venture investment vehicle for QB3), the External Advisory Board for the Lewis Sigler Institute of Quantitative Genomics at Princeton, and is the Chairman of the Scleroderma Research Foundation.
Catherine Friedman has served as one of our directors since May 2007. Ms. Friedman currently is an independent financial consultant serving private and public companies in the lifesciences. Prior to that, Ms. Friedman held numerous positions over a 23 year investment banking career with Morgan Stanley. Ms. Friedman held the position of Managing Director at Morgan Stanley from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. Ms. Friedman joined the board of XenoPort Inc., a publicly-held biopharmaceutical company, in September 2007 and also serves on its audit committee.
Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer is a member of the board of directors for BrainCells, EnteroMedics, Etex Corporation, MAP Pharmaceuticals, Metabolex, Nevro Corporation, Poniard Pharmaceuticals, and PTC Therapeutics. He is also a member of the Board of Trustees of Mt. Zion Hospital. Dr. Goldfischer received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.
Bobby I. Griffin has served as one of our directors since September 2006. In 1998, Mr. Griffin retired from a 25 year career with Medtronic Corporation, where he held various positions, including Executive Vice President from 1985 to 1998 and President of Medtronic's Pacemaker Business from 1991 to 1998. Since his retirement, Mr. Griffin has been a private investor, managing his own fund of companies as well as serving on the advisory boards of Affinity Capital Management Fund III and IV and Sapient Capital Management Fund, in which he also invests. In addition, Mr. Griffin has served on the board of directors of several public companies, including MTS Systems Corporation and Urologix, Inc. and is currently a director of several private companies.
Donald C. Harrison, M.D. has served as one of our directors since September 2003. He is currently Managing Partner of Charter Life Sciences, a venture capital firm, where he has served since 2003. From 1986 to 2003, Dr. Harrison was Chief Executive Officer of the University of Cincinnati Medical Center. Dr. Harrison is a member of the board of Kendle International Inc., a publicly-held global clinical research organization, and AtriCure, Inc., a publicly-held company that develops innovative products for tissue ablation during surgical procedures, and also serves on the audit committees of both of these companies.
Paul H. Klingenstein has served as one of our directors since July 2006. He has served as Managing Partner of Aberdare Ventures since its formation in 1999. Formerly, he served as a General Partner of Accel Partners, as a Consultant to the Rockefeller Foundation, and as an employee of E.M. Warburg, Pincus & Co. Mr. Klingenstein serves on the boards and audit committees of several private companies.
Nicholas L. Teti, Jr. has served as one of our directors since May 2007. Mr. Teti is currently an independent consultant serving public and private health care companies. Mr. Teti 's most recent assignment was Chief Executive Officer of Den-Mat, a dental aesthetics company focused on developing non-invasive techniques, a position he held from January 2008 until March 2009. Since June 2006, he has also served as Chairman of the Board of Isolagen, Inc., a biotechnology company which develops emergent, novel skin and tissue rejuvenation technologies. From June 2006 to January 2008, Mr. Teti was Chief Executive Officer of Isolagen. From 2001 to 2006, Mr. Teti was President and Chief Executive Officer of Inamed Corporation, a healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles, and devices to treat severe and morbid obesity, including the LAP-BAND Adjustable Gastric Banding System. Mr. Teti served on the board of Inamed during 2001 and was Chairman of the Board from 2002 to 2006. Prior to that, Mr. Teti spent 25 years at DuPont and DuPont Merck where he held a number of senior management positions including President and CEO of DuPont Pharmaceuticals.
Jon T. Tremmel
Jon T. Tremmel has served as one of our directors since January 2009. Over the course of his career at Medtronic, Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division, President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves as a Board Member for a number of corporate and civic organizations.
EnteroMedics - 2800 Patton Road - St. Paul,
MN 55113
CAUTION: Investigational device. Limited by Federal law to
investigational use.
This page revised May 2009.
show all
hide all
